SAVE THE DATE
Vessel of Hope: An Evening of Art
Friday, December 7 • 6– 8 p.m.
In partnership with Creative Arts in Healing and Cancer Treatment Centers of America.
This social program offers a juried art exhibit showcasing ceramic vessels from artists of all ages. Vessels of Hope is an art project that provides a unique opportunity for potters and ceramic artists to make a difference in the life of a cancer patient, survivor or caregiver.
Enjoy light refreshments as you view art that depicts the interpretation of hope for those on the cancer journey.
Please RSVP by calling The Wellness Community – Arizona at (602) 712-1006.
Vismodegib, a new skin cancer drug tested by the Translational Genomics Research Institute (TGen), Scottsdale Healthcare (SHC) and Mayo Clinic, was recently hailed as “the greatest advance in therapy yet seen” for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine.
This is the first drug tested under the SHC-TGen partnership to receive FDA approval, and is the first to receive FDA approval to treat inoperable basal cell carcinoma.
The successful Phase I study, headed by and TGen Physician-In-Chief and SHC Chief Scientific Officer Dr. Daniel Von Hoff, led to a broader study.
The follow-up study, a Phase 2 clinical trial of basal cell carcinoma, was headed by Dr. Aleksandar Sekulic, Assistant Professor of Dermatology for the Mayo Clinic in Arizona, and an Assistant Professor in TGen’s Integrated Cancer Genomics Division.
PR610 is designed to activate in tissues with low levels of oxygen, which is characteristic of many cancers. This “targeted” approach should deliver more active drug to cancer tissue and less active drug to normal tissue.
The study will evaluate the safety and efficacy of PR610 when given to patients with non-small cell lung cancer whose tumors contain a certain genetic mutation.
Find out more at tgen.org.